Hepatology Research

Article	Citations
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”	145
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis	137
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan	129
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs	98
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval	76
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation	60
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome	54
Factors associated with portopulmonary hypertension	52
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?	44
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	41
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ	38
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma	37
Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	36
Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers	34
The change from NAFLD to MAFLD expands fatty liver information flow	33
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases	32
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	32
Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral re	29
Prognostic value of virtual portal pressure gradient response in compensated cirrhotic patients treated with carvedilol	28
Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocel	26
RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury	26
Transcriptomic and proteomic studies suggest the establishment of advanced zonation‐like profiles in human‐induced pluripotent stem cell‐derived liver sinusoidal endothelial cells and carboxypeptidase	25
Issue Information	23
Issue Information	23
Issue Information	23

Molecular biological role of epithelial splicing regulatory protein 1 in intrahepatic cholangiocarcinoma	21
	21
Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria	21
	20
Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus‐related liver cirrhosis	19
Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021	19
Magnetic resonance imaging‐based risk factors of hepatocellular carcinoma after direct‐acting antiviral therapy: A multicenter observational study	19
Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management	19
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease	18
Chronic liver disease questionnaire to manage patients with chronic liver diseases	17
	17
What can we create by adding robotic assistance to conventional laparoscopic liver resection?	17
Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months	17
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study	17
Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis	16
Differential peripheral memory T cell subsets sensitively indicate the severity of nonalcoholic fatty liver disease	16
Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR‐3619‐5p/SOX9	16
Issue Information	16
Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures	15
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era	15
Measurement of spleen length and two‐dimensional spleen index is comparable to spleen volumetry by computed tomography for predicting esophageal varices	15
	15
Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome	14
Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study	14
Quantitative evaluation of tumor signal heterogeneity on gadoxetic acid‐enhanced magnetic resonance imaging as a predictor of postoperative survival and antitumor immunity in hepatocellular carcinoma	14
Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography	14
Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	14
Weighted thyroid‐stimulating hormone disturbance in prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure	14
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	14
Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma	14
Moderate‐carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: A prospective cohort study	14
	13
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	13
	13
Comparison of modified CEUS LI‐RADS with sonazoid and CT/MRI LI‐RADS for diagnosis of hepatocellular carcinoma	13
Predictive model containing gene signature and shear wave elastography to predict patient outcomes after Kasai surgery in biliary atresia	13
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex	13
Cost‐effectiveness of hepatitis E virus vaccination strategy	12
Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects	12
Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians	12
Spleen stiffness in patients with chronic liver disease evaluated by 2‐D shear wave elastography with ultrasound multiparametric imaging	12
Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma	12
Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis	12
Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing living‐donor liver transplantation: Single‐center controlled trial	11
Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation	11
	11
Immunovascular microenvironment in relation to prognostic heterogeneity of WNT/β‐catenin‐activated hepatocellular carcinoma	11
	11
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study	11
Comparison between splenic dispersion slope and splenic shear wave speed on ultrasound elastography for predicting esophageal varices	10

Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body	10
	10
Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study	10
Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan	10
The role of the nervous system in liver diseases	10
Perturbation of Wnt/β‐catenin signaling and sexual dimorphism in non‐alcoholic fatty liver disease	9
Steroid administration for ischemic complications after radiofrequency ablation: A retrospective study	9
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	9
Non‐malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors	9
Real‐world efficacy of radiomics versus clinical predictors for microvascular invasion in patients with hepatocellular carcinoma: Large cohort study	9
Issue Information	9
Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID‐19	9
Issue Information	9
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease	9
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients	9
Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan	9
Erratum	9
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	8
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	8
Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021	8
Issue Information	8
Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis	8
Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation	8
	8
Evaluating the liver function of patients with hepatocellular carcinoma	8
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma	8
Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan	8
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population	8
Issue Information	8
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	8
Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups	7
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease	7
	7
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	7
Analysis of non‐severe acute onset autoimmune hepatitis according to the presence of radiological heterogeneity	7
Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification	7
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus‐related hepatocellular carcinoma	7
High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma	7
Clinical significance of the latency period of abnormal ammonia metabolism in chronic liver disease: Proposal of a new concept	7
	7
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients	7
Issue Information	7
Cost‐effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China	7
Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease	7
Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy	7
A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	7
Metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease?	7
Impact of liver fibrosis on the relative abundance of a urease‐positive Streptococcus salivarius group from saliva in patients with chronic liver disease	7
Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data	7
Acknowledgment	6
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020	6
A classification model for resectability in hepatocellular carcinoma patients	6
Acknowledgment	6
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease	6
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis	6
Novel strategies for the early diagnosis of hepatitis B virus reactivation	6
Clinical benefits of partial splenic embolization for cancer patients	6
Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis	6
Seroprevalence and incidence of hepatitis E virus infection in the general population of Iwate prefecture, Japan: A retrospective cohort study	6
Disability in perioperative activities of daily living is associated with worse survival outcomes following hepatic resection in patients with intrahepatic cholangiocarcinoma	6
Pathological significance of intranuclear structures in liver biopsy samples	6
Effects of weight loss on metabolic dysfunction‐associated fatty liver disease in Japanese people: Non‐alcoholic fatty liver disease in the Gifu area, longitudinal analysis study	6
Dried blood spot‐based host genome analysis technique targeting pathological associations with hepatitis B: Development and clinical application in the Cambodian population	6
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen®, for people living with HIV	6
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis	6
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs	6
Acknowledgments	6
Issue Information	6
Issue Information	6
Fibroblast growth factor receptor 2 alterations in intrahepatic cholangiocarcinoma: Prevalence and clinical implications in Asian populations	6
	6
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	6
Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan	6
Efficacy of antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus and the risk of postpartum hepatitis flare after discontinuation of antiviral therapy	6
Optimal treatment strategy and prognostic analysis of salvage liver transplantation for patients with early hepatocellular carcinoma recurrence after hepatectomy	5
Cachexia is an independent predictor of mortality in patients with cirrhosis	5
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	5
Issue Information	5
Corrigendum	5
	5

	5
The promise of radiotherapy for hepatocellular carcinoma	5
New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study	5
Developing a feasible classification model for surgical hepatocellular carcinoma: More questions than answers	5
Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease	5
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study	5
High serum gamma‐glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma	5
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice	5
Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in healt	5
Exosomal circCMTM3 promotes the pathogenesis of hepatocellular carcinoma via angiogenesis	5
Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults	5
An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images	5
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis	5
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease	5
	5
Serum pro‐inflammatory cytokine interleukin‐6 level is predictive of further decompensation and mortality in liver cirrhosis	5
The impact of the COVID‐19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study	5
Issue Information	5